Memorandum

Subject: Process to implement Act 529 to allow Arkansas APRNs with an active Prescriptive Authority Certificate (PAC) and DEA number to prescribe hydrocodone combination products from Schedule II of the Controlled Substance Act.

Process:
1. APRN will submit to the ASBN a new/updated Collaborative Practice Agreement (CPA) to include:
   A. Language that authorizes the APRN to prescribe drugs listed in Schedules III – V and hydrocodone combination products from Schedule II of the Controlled Substance Act. For example, “The above named APRN is authorized to prescribe drugs listed in Schedules III – V and hydrocodone combination products from Schedule II of the Controlled Substances Act."
   B. APRN’s name and license number
   C. Current business/practice address and phone number
   D. Signatures of both the APRN and collaborating physician/s
2. The new/updated CPA will be reviewed and approved by the ASBN staff.
3. The ASBN staff will notify the DEA that the APRN has met the requirements for prescribing hydrocodone combination products.
4. The DEA will complete their process to allow the APRN to prescribe hydrocodone combination products and Schedules III – V. The APRN should verify the completion of this process on the DEA website.
5. Per the Chapter 4 Rules, the APRN must submit a copy of the updated DEA registration to the ASBN.
6. APRNs should update their Prescriptive Protocols to include the addition of hydrocodone combination products. Protocols should NOT be submitted to the ASBN unless requested.

Prescribing Privileges: APRNs can begin prescribing hydrocodone combination products when the APRN has received written notification from the ASBN that their CPA has been approved and can verify on the DEA website that they have been authorized to prescribe Schedules III – V and the hydrocodone combination products from Schedule II.

*Templates for CPAs can be located on the ASBN website (www.arsbn.org) under the Adv. Practice tab. APRNs are welcome to use these templates.